TCGA-QK-AA3J-01A-11R-A39I-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- G2M_CHECKPOINT+0.260
- E2F_TARGETS+0.170
- KRAS_SIGNALING_DN+0.170
- FATTY_ACID_METABOLISM+0.140
- ANDROGEN_RESPONSE+0.130
- MITOTIC_SPINDLE+0.130
- SPERMATOGENESIS+0.120
- APICAL_SURFACE+0.090
- PEROXISOME+0.070
- BILE_ACID_METABOLISM+0.050
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.610
- ANGIOGENESIS-0.510
- UNFOLDED_PROTEIN_RESPONSE-0.390
- HYPOXIA-0.370
- IL6_JAK_STAT3_SIGNALING-0.360
- INFLAMMATORY_RESPONSE-0.350
- INTERFERON_ALPHA_RESPONSE-0.350
- ALLOGRAFT_REJECTION-0.340
- COMPLEMENT-0.340
- MTORC1_SIGNALING-0.340
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-G2-AA3D-01A-11R-A39I-07 | — | — | 0.881 |
| 2 | TCGA-ZF-AA4X-01A-11R-A38B-07 | — | — | 0.873 |
| 3 | TCGA-LT-A5Z6-01A-11R-A28M-07 | — | — | 0.865 |
| 4 | TCGA-CN-4739-01A-02R-1514-07 | — | — | 0.864 |
| 5 | TCGA-FJ-A3ZF-01A-11R-A23N-07 | — | — | 0.864 |
| 6 | TCGA-CN-5374-01A-01R-1436-07 | — | — | 0.845 |
| 7 | SRR650147 | — | — | 0.839 |
| 8 | TCGA-GV-A3JW-01A-11R-A20F-07 | — | — | 0.839 |
| 9 | TCGA-ZF-A9RL-01A-11R-A38B-07 | — | — | 0.838 |
| 10 | TCGA-GU-A42P-01A-11R-A23W-07 | — | — | 0.837 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 11 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| G2M_CHECKPOINT | 0.260 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.170 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.170 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.140 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.130 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.130 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.120 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.090 | Temsirolimus | — uncovered |
| PEROXISOME | 0.070 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.050 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.050 | Remibrutinib | — uncovered |